Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Univariable analysis of associations between morphometric vertebral fractures and baseline characteristicsRate ratio95% CIpAllocation of osteoporosis treatmentBisphosphonate monotherapy(Reference = Teriparatide → Alendronate sequential therapy)1.461.081.980.01*Age (y)1.041.011.070.02*Age at menopause (y)1.000.971.030.93Years from menopause1.021.001.040.09Count of pre-existing vertebral fractures1.221.161.29 < 0.01*Maximum grade of pre-existing vertebral fractures NoneReference Grade 110.334.8921.82 < 0.01* Grade 210.685.2821.59 < 0.01* Grade 37.733.9015.31 < 0.01*History of proximal femoral fractures0.790.501.230.29Prior treatment0.790.601.050.11Prior bisphosphonates0.930.681.270.66BMD at L2-L4 (T-score)0.840.720.980.03*Comorbidity Hypertension0.990.741.330.97 Diabetes mellitus0.780.451.380.40 Dyslipidemia1.230.861.750.25 Rheumatoid arthritisNot estimable Osteoarthritis3.380.4724.090.22 Others1.210.901.630.21MMSE0.980.951.010.25Timed-up-and-go test (seconds)1.011.001.020.05One-leg standing test (seconds)0.990.981.000.05Nursing level Support not requiredReference Support required1.150.751.770.53 Level 11.941.143.300.01* Level 20.350.091.400.14 Level 30.800.203.210.75 Level 4 or 51.280.325.150.73Number of teeth present0.980.971.000.05Height (cm)0.960.940.98 < 0.01*Weight (kg)0.970.950.99 < 0.01*BMI < 18.5 kg/m20.890.581.380.61BMI 18.5 to 24 kg/m2ReferenceBMI ≥ 25 kg/m20.870.601.250.44Systolic blood pressure (mmHg)1.000.991.010.78Diastolic blood pressure (mmHg)1.000.981.010.44Osteocalcin (ng/mL)1.000.981.010.50PINP (μg/L)1.001.001.000.67TRACP-5b (per 100 mU/dL)1.101.041.17 < 0.01*25(OH)D (ng/mL)0.990.961.010.33Pentosidine (pmol/mL)1.011.001.01 < 0.01*Corrected pentosidine (pmol/mL∙Cr)1.001.001.010.35HbA1C (%)0.710.520.960.03*Total cholesterol (mg/dL)0.990.991.00 < 0.01*HDL cholesterol (mg/dL)1.011.001.020.03*LDL cholesterol (mg/dL)0.990.991.00 < 0.01*Triglyceride (mg/dL)0.990.991.00 < 0.01*eGFR (mL/min/1.73 m2)0.990.981.000.07Creatinine (mg/dL)1.470.792.740.23Urine creatinine (mg/dL)1.001.001.01 < 0.01*Albumin (g/dL)0.600.410.900.01*Ca (mg/dL)1.020.741.400.92Urine Ca (mg/dL)1.010.991.020.54VAS at rest (per 10 points from 0 to 100 points)1.131.081.19 < 0.01*VAS on motion (per 10 points from 0 to 100 points)1.091.051.14 < 0.01*EQ-5D (utility)0.330.150.71 < 0.01*Alcohol intake1.001.001.01 < 0.01*Energy intake1.001.001.000.98Protein intake1.000.991.000.35Fat intake1.000.991.000.34Carbohydrate intake1.001.001.000.66Salt intake1.050.981.130.16Ca intake1.001.001.000.69Fe intake1.000.941.061.00Vitamin A intake1.001.001.000.32Vitamin D intake1.010.951.060.82Vitamin K intake1.001.001.000.80Vitamin B1 intake0.870.471.610.65Vitamin B2 intake0.990.711.370.94Vitamin B6 intake0.880.541.420.59Vitamin B12 intake0.980.951.020.41Folic acid intake1.001.001.000.80Vitamin C intake1.000.991.000.67Mg intake1.001.001.000.74*p < 0.05CI confidence interval, BMD bone mineral density, MMSE Mini-Mental State Examination, BMI body mass index, PINP procollagen type 1 N-terminal propeptide, TRACP-5b tartrate-resistant acid phosphatase-5b, 25(OH)D 25-hydroxyvitamin D, HbA1C hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration rate, Ca calcium, VAS visual analog scale, EQ-5D The EuroQol 5 dimensions, Fe iron, Mg magnesium
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Secondary analysis.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Predictors of vertebral fractures in patients with severe osteoporosis: a sub-analysis of the Japanese Osteoporosis Intervention Trial-05 (JOINT-05)
Source: Article title.
This was a post hoc analysis of data of 778 women aged ≥ 75 years with severe osteoporosis from the JOINT-05 trial.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Predictors of vertebral fractures in patients with severe osteoporosis: a sub-analysis of the Japanese Osteoporosis Intervention Trial-05 (JOINT-05)
Secondary analysis · Archives of Osteoporosis · 2025
Original publication title
Predictors of vertebral fractures in patients with severe osteoporosis: a sub-analysis of the Japanese Osteoporosis Intervention Trial-05 (JOINT-05)
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Vertebral fractures (VFs) are a major cause of morbidity and economic burden in aging populations. Despite effective osteoporosis treatments, VF incidence continues to increase. This study aimed to identify predictors for incident VFs in elderly women with severe osteoporosis.
Source: PurposeAbstract: What methods does the paper describe?
This was a post hoc analysis of data of 778 women aged ≥ 75 years with severe osteoporosis from the JOINT-05 trial. We investigated potential predictors for incident VFs, including the burden of prevalent vertebral fractures (number and Genant grade), prior osteoporosis treatment, lipid profile (e.g., triglycerides), low back pain VAS, physical function (timed-up-and-go, one-leg standing), and nutritional indices (e.g., albumin, selected nutrients from the Food Frequency Questionnaire). Multivariate Poisson regression analysis was used to identify independent predictors.
Source: MethodsAbstract: Summary
Incident vertebral fractures are a major issue in elderly women with severe osteoporosis. Beyond well-established risk factors, osteoporosis treatment given, low serum triglyceride levels, and intensity of low back pain were identified as predictors of new fractures in high-risk elderly women. Clinical strategies need to take these findings into account.
Source: SummaryAbstract: Results
During the study, 138 participants (17.7%) developed incident VFs. The allocated osteoporosis treatment, the number and grade of pre-existing VFs, prior history of osteoporosis treatment, lower serum triglyceride levels, and the low back pain score were significant predictors of incident VFs. VF incidence was significantly higher in patients with pre-existing VFs, although risk did not increase with the severity of existing VFs.
Source: ResultsAbstract: Conclusion
Beyond established risk factors such as pre-existing fractures, this study identified the allocation of osteoporosis treatment, low serum triglyceride levels, and the intensity of low back pain as independent predictors of new VFs in high-risk elderly women. Thus, clinical strategies to prevent subsequent fractures should include optimizing pharmacological treatment (e.g., sequential therapy with teriparatide), considering lipid status, and implementing effective, multimodal pain management.
Source: ConclusionAuthors’ abstract
Summary
Incident vertebral fractures are a major issue in elderly women with severe osteoporosis. Beyond well-established risk factors, osteoporosis treatment given, low serum triglyceride levels, and intensity of low back pain were identified as predictors of new fractures in high-risk elderly women. Clinical strategies need to take these findings into account.
Purpose
Vertebral fractures (VFs) are a major cause of morbidity and economic burden in aging populations. Despite effective osteoporosis treatments, VF incidence continues to increase. This study aimed to identify predictors for incident VFs in elderly women with severe osteoporosis.
Methods
This was a post hoc analysis of data of 778 women aged ≥ 75 years with severe osteoporosis from the JOINT-05 trial. We investigated potential predictors for incident VFs, including the burden of prevalent vertebral fractures (number and Genant grade), prior osteoporosis treatment, lipid profile (e.g., triglycerides), low back pain VAS, physical function (timed-up-and-go, one-leg standing), and nutritional indices (e.g., albumin, selected nutrients from the Food Frequency Questionnaire). Multivariate Poisson regression analysis was used to identify independent predictors.
Results
During the study, 138 participants (17.7%) developed incident VFs. The allocated osteoporosis treatment, the number and grade of pre-existing VFs, prior history of osteoporosis treatment, lower serum triglyceride levels, and the low back pain score were significant predictors of incident VFs. VF incidence was significantly higher in patients with pre-existing VFs, although risk did not increase with the severity of existing VFs.
Conclusion
Beyond established risk factors such as pre-existing fractures, this study identified the allocation of osteoporosis treatment, low serum triglyceride levels, and the intensity of low back pain as independent predictors of new VFs in high-risk elderly women. Thus, clinical strategies to prevent subsequent fractures should include optimizing pharmacological treatment (e.g., sequential therapy with teriparatide), considering lipid status, and implementing effective, multimodal pain management.
Publication and source details
Original title: Predictors of vertebral fractures in patients with severe osteoporosis: a sub-analysis of the Japanese Osteoporosis Intervention Trial-05 (JOINT-05)
Hiroyuki Inose; Shiro Tanaka; Satoshi Mori; Hiroshi Hagino; Satoshi Soen
Archives of Osteoporosis · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.the Public Health Research Foundationhttp://dx.doi.org/10.13039/100010740Asahi Kasei Pharma CorporationRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T01:09:14.813067+00:00
DOI: 10.1007/s11657-025-01649-7 · PMC12702800